Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice

Diabetes

Volumn 58, Issue 8, 2009, Pages 1739-1748

  Tu, Powen ^a   Bhasin, Shalender ^a,b   Hruz, Paul W ^c   Herbst, Karen L ^d   Castellani, Lawrence W ^e   Hua, Ning ^a   Hamilton, James A ^a   Guo, Wen ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; DEOXYGLUCOSE; FATTY ACID; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOSTATIN; TRIACYLGLYCEROL; TRITIUM; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY COMPOSITION; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG TARGETING; DYSLIPIDEMIA; FATTY ACID OXIDATION; FATTY LIVER; GENE INACTIVATION; GLUCOSE TOLERANCE TEST; HYPERINSULINEMIA; IMAGING SYSTEM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; LIPID DIET; MAGNETIC RESONANCE ANGIOGRAPHY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SPECTROMETER; WESTERN BLOTTING;

ADIPOSE TISSUE; ANIMALS; ATHEROSCLEROSIS; BLOOD GLUCOSE; BODY COMPOSITION; DYSLIPIDEMIAS; GENE DELETION; GLUCAGON; INSULIN; LIPIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; MYOSTATIN; RECEPTORS, LDL;

EID: 68049117225     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-0349     Document Type: Article

References (39)

1. Sloan FA, Bethel MA, Ruiz DJ, Shea AM., MN F. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med 2008;168:192-199
2. Ding J, Kritchevsky SB, Newman AB, Taaffe DR, Nicklas BJ, Visser M, Lee JS, Nevitt M, Tylavsky FA, Rubin SM, Pahor M, Harris TB. Effects of birth cohort and age on body composition in a sample of community-based elderly. Am J Clin Nutr 2007;85:405-410
3. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90
4. Amthor H, Huang R, McKinnell I, Christ B, Kambadur R, Sharma M, Patel K. The regulation and action of myostatin as a negative regulator of muscle development during avian embryogenesis. Dev Biol 2002;251:241-257
5. Artaza JN, Bhasin S, Magee TR, Reisz-Porszasz S, Shen R, Groome NP, Meerasahib MF, Gonzalez-Cadavid NF. Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells. Endocrinology 2005;146:3547-3557
6. McPherron AC, Lee SJ. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 2002;109:595-601
7. Lee SJ. Regulation of muscle mass by myostatin. J Clin Invest 2004;20:61-86
8. Breslow JL. Mouse models of atherosclerosis. Science 1996;272:685-688
9. Wilkes JJ, Lloyd DJ, Gekakis N. A loss-of-function mutation in myostatin reduces TNF-α production and protects liver against obesity-induced insulin resistance. Diabetes 2009;58:1133-1143
10. Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, McPherron AC. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS ONE 2009;4:e4937
11. Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viereck J, Hamilton JA, Ouchi N, LeBrasseur NK, Walsh K. Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 2008;7:159-172
12. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007;447:959-965
13. Hedrick CC, Castellani LW, Warden CH, Puppione DL, Lusis AJ. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem 1993;268:20676-20682
14. Innis-Whitehouse W, Li X, Brown WV, Le NA. An efficient chromatographic system for lipoprotein fractionation using whole plasma. J Lipid Res 1998;39:679-690
15. Hruz PW, Murata H, Qiu H, Mueckler M. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 2002;51:937-942
16. Folch J, Ascoli I, Lees M, Meath JA, Le BN. Preparation of lipide extracts from brain tissue. J Biol Chem 1951;191:833-841
17. Kuipers F, Jong MC, Lin Y, Eck M, Havinga R, Bloks V, Verkade HJ, Hofker MH, Moshage H, Berkel TJ, Vonk RJ, Havekes LM. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J Clin Invest 1997;100:2915-2922
18. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, Despres JP. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996;94:273-278
19. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-2033
20. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119
21. Ginsberg HN. Very low density lipoprotein metabolism in diabetes mellitus. Diabetes Metab Rev 1987;3:571-589
22. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997;40:454-462
23. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000;6:77-86
24. Leow MK, Addy CL, Mantzoros CS. Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003;88:1961-1976
25. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, Li S, Yang W, Pei L, Uldry M, Tontonoz P, Newgard CB, Spiegelman BM. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 2005;120:261-273
26. Stefanovic-Racic M, Perdomo G, Mantell BS, Sipula IJ, Brown NF, RM OD. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am J Physiol Endocrinol Metab 2008;294:E969-E977
27. Fritsche L, Weigert C, Haring HU, Lehmann R. How insulin receptor substrate proteins regulate the metabolic capacity of the liver-implications for health and disease. Curr Med Chem 2008;15:1316-1329
28. Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK, Bergman RN. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 2005;288:E454-E461
29. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004;279:32345-32353
30. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 2004;24:644-649
31. Guo W, Flanagan J, Jasuja R, Kirkland J, Jiang L, Bhasin S. The effects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signaling pathways. J Biol Chem 2008;283:9136-9145
32. Feldman BJ, Streeper RS, Farese RV, Jr, Yamamoto KR. Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects. Proc Natl Acad Sci U S A 2006;103:15675-15680
33. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001;27:195-200
34. Thorens B, Charron MJ, HF L. Molecular physiology of glucose transporters Diabetes Care 1990;3:209-218
35. Abu-Elheiga L, Oh W, Kordari P, Wakil SJ. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high- carbohydrate diets. Proc Natl Acad Sci U S A 2003;100:10207-10212
36. Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP. Role of myokines in exercise and metabolism. J Appl Physiol 2007;103:1093-1098
37. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett 2008;582:3805-3810
38. Ouchi N, Oshima Y, Ohashi K, Higuchi A, Ikegami C, Izumiya Y, Walsh K. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 2008;283:32802-32811
39. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, JR. M. Phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;65:543-545